Inovio Pharmaceuticals, Inc. Form 8-K (Feb. 7, 2020)

Summary

Inovio Pharmaceuticals, Inc. reported in this Form 8-K that on February 7, 2020 it amended its At-The-Market Equity Offering Sales Agreement dated May 25, 2018 with Stifel, Nicolaus & Company, Incorporated. The amendment raises the aggregate offering price of common stock that can be sold through Stifel from up to $100,000,000 to up to $200,000,000. The filing says the company has sold approximately $68.3 million of its common stock since September 30, 2019 and $100 million since May 25, 2018 under the agreement. Exhibits include the amendment and an opinion and consent of Cooley LLP. Peter Kies signed on February 7, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

8-K 1 d858444d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT
REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2020

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-14888 | 33-0969592
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)

660 W. Germantown Pike, Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or
former address, if changed since last report)

Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.001 par value | INO | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On February 7, 2020, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an amendment (the
“ Amendment ”) to the At-The-Market Equity Offering Sales Agreement dated May 25, 2018 (as amended, the “ Sales
Agreement ”) with Stifel, Nicolaus & Company, Incorporated (“ Stifel ”), which amendment increases the amount of Company common stock, par value $0.001 per share (the “ Common
Stock ”), that can be sold by the Company through Stifel as its sales agent under the Sales Agreement from an aggregate offering price of up to $100,000,000 to an aggregate offering price of up to $200,000,000.

Pursuant to the Sales Agreement, sales of the Common Stock, if any, will be made under the Company’s previously filed and effective
Registration Statement on Form S-3 (File No. 333- 225233) and an applicable prospectus supplement, by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4)
under the Securities Act of 1933, as amended. Since September 30, 2019 the Company has sold approximately $68.3 million of its common stock pursuant to the Agreement and since May 25, 2018 has sold $100 million of its common stock
pursuant to the Agreement.

The Sales Agreement is attached or incorporated by reference to this Current Report on Form 8-K as Exhibits 1.1 and 1.2 and is incorporated herein by reference. The foregoing description of the material terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to
the exhibits attached hereto.

This Current Report on Form 8-K shall not constitute an offer to
sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.

Item 9.01. Financial Statements and Exhibits.

Exhibit No. | Exhibit Description
1.1 | At-The-Market Equity Offering Sales Agreement dated May 25, 2018 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated
 (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed May 25, 2018).
1.2 | Amendment No. 1 to the At-The-Market Equity Offering Sales Agreement dated February
7, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated.
5.1 | Opinion of Cooley LLP.
23.1 | Consent of Cooley LLP (included in Exhibit 5.1).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.
Date: February 7, 2020 | By: | /s/ Peter Kies
Peter Kies
Chief Financial Officer

File and source

File

SEC_INO_8-K_filed2020-02-07_0001193125-20-028310.htm

Size

19,755 bytes

SHA-256

f460fa9c861d1da13eae266d13e56bf7b1146f4a2d9535baf1207605bd8503ee

Our copy

SEC_INO_8-K_filed2020-02-07_0001193125-20-028310.htm

Original

www.sec.gov